Proposed is a laser enhancer composition for improving melasma, wrinkles, skin tightening, pores, and acne by removing dead skin cells on an epidermal layer of the skin. The laser enhancer composition is used in a form applied to the epidermal layer during the treatment. The laser enhancer composition includes: either one or both of a peeling material and a heat conducting material that are configured not to be vaporized by a laser so that fumes are not generated; a viscous material configured to mix the peeling material 11a and the heat conducting material due to viscosity thereof; a volatile alcohol; and purified distilled water.

Methods and systems are provided for producing ionized alkaline solutions (e.g. ionized alkaline water) that exhibit long-term stability when stored at room temperature.

A method and system that is directed to the local delivery of growth factors to the mammalian CNS to treat CNS disorders associated with neuronal death and/or dysfunction is described.

An environmentally sensitive membrane binding polypeptide, pH (low)-sensitive membrane peptide (pHLIP) has improved insertion kinetics balanced with solubility to selectively target acidic tissues.

The present invention relates to a column chromatographic method of manufacturing non-carrier-added high-purity .sup.177Lu compounds for medicinal purposes. In the method in accordance with the invention a cation exchanger and a suitable chelating agent are used. With the method in accordance with the invention it is possible for the first time to provide non-carrier-added high-purity .sup.177Lu compounds in milligram amounts for pharmaceutical-medicinal purposes from .sup.176Yb compounds irradiated with thermal neutrons, the radionuclides .sup.177Lu and .sup.176Yb being present in an approximate mass ratio of 1:10.sup.2 to 1:10.sup.10 for purification.

Iron garnet nanoparticles and or iron garnet particles containing various activatable nuclides, such as holmium-165 (.sup.165Ho) and dysprosium-164 (.sup.164Dy), are disclosed in this application. The iron garnet (e.g., HoIG and DyIG) nanoparticles and iron garnet particles can prepared using hydroxide co-precipitation methods. In some embodiments, radiosensitizers can be loaded on radioactive magnetic nanoparticles or radioactive iron garnet particles and, optionally, coated with suitable lipid bilayers. Methods of using the disclosed nanoparticles and particles for mediating therapeutic benefit in diseases responsive to radiation therapy are also provided. Another aspect of the invention provides films, electrospun fabrics or bandage coverings for the delivery of radiation to the site of a skin lesion amenable to treatment with radiation (e.g., skin cancers or psoriasis).

A radiopaque particulate material one or more of SiO.sub.2, TiO.sub.2, La.sub.2O.sub.3, Na.sub.2O and MgO and useful for embolization which optionally includes therapeutic components that are released in vivo.

The disclosure is directed to a spherical particle comprising lanthanide hydroxide, a method of preparing the particle, the particle for use in medical applications, a suspension, a composition, a method of obtaining a scanning image, and the particle for use in the treatment of a subject.

The disclosure is directed to a spherical particle comprising lanthanide hydroxide, a method of preparing the particle, the particle for use in medical applications, a suspension, a composition, a method of obtaining a scanning image, and the particle for use in the treatment of a subject.

Described herein are compositions and methods relating to molecular cerium-oxide nanoclusters. In an aspect, described herein are methods of synthesizing molecular cerium-oxide nanocluster compositions and compositions thereof. In an aspect, described herein are methods of scavenging reactive oxygen species utilizing molecular cerium-oxide nanoclusters as described herein. Also described herein are pharmaceutical compositions and methods of use. Pharmaceutical compositions as described herein can comprise a therapeutically effective amount of a compound (such as a composition comprising one or more molecular cerium-oxide nanoclusters), or a pharmaceutically acceptable salt of the compound, and a pharmaceutically acceptable carrier. Methods of treating oxidative stress are also described herein, comprising administering pharmaceutical compositions as described herein to a subject in need thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.